Huyen Tran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Huyen Tran has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Aktham Aburub
Synthetic Molecule Design and Development (,) Eli Lilly and Company, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285
3 shared publicationsMohamed E. H. ElSayed
2 shared publicationsSelina Estwick
2 shared publicationsSiyuan Huang
Synthetic Molecule Design and Development (,) Eli Lilly and Company, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285
2 shared publications- Aktham Aburub
Synthetic Molecule Design and Development, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, USA
1 shared publication - Amita Datta-Mannan
Eli Lilly and Company Indianapolis Indiana USA
1 shared publication
Latest Publications
- 20 October 2026
- Published by American Chemical Society (ACS) in The Journal of Physical Chemistry B
- Vol. 130 (43) , 11474-11483
Simulating the Permeation of a Therapeutic Peptide through a Phospholipid Membrane
Oral peptide delivery offers a promising route for therapeutic administration but is often hampered by challenges related to the low permeability of peptides across gastrointestinal epithelia. This study employs state-of-the-art molecular dynamics (MD) simulations and enhanced sampling methods (i.e., well-tempered metadynamics extended-system adaptive biasing force, coined WTM-eABF) to investigate the simultaneous folding/unfolding of a linear 39 amino acid peptide with and without a fatty acid modification as it permeates a POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) membrane. The resulting free energy surfaces capture the simultaneous secondary structural changes and the translocation process of the peptides, which are carefully examined against well-established, independent free-energy calculations at key steps in the permeation process. The free-energy surfaces indicate that the peptides assume a more structured configuration upon membrane interaction. The results show that the permeation of neutral peptides, despite their large size, is nearly barrierless. In addition, the simulations show that WTM-eABF is able to qualitatively converge the free energy of the permeation of long, flexible peptides.
- 20 October 2026
- Published by American Chemical Society (ACS) in The Journal of Physical Chemistry B
- Vol. 130 (43) , 11474-11483
Simulating the Permeation of a Therapeutic Peptide through a Phospholipid Membrane
Oral peptide delivery offers a promising route for therapeutic administration but is often hampered by challenges related to the low permeability of peptides across gastrointestinal epithelia. This study employs state-of-the-art molecular dynamics (MD) simulations and enhanced sampling methods (i.e., well-tempered metadynamics extended-system adaptive biasing force, coined WTM-eABF) to investigate the simultaneous folding/unfolding of a linear 39 amino acid peptide with and without a fatty acid modification as it permeates a POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) membrane. The resulting free energy surfaces capture the simultaneous secondary structural changes and the translocation process of the peptides, which are carefully examined against well-established, independent free-energy calculations at key steps in the permeation process. The free-energy surfaces indicate that the peptides assume a more structured configuration upon membrane interaction. The results show that the permeation of neutral peptides, despite their large size, is nearly barrierless. In addition, the simulations show that WTM-eABF is able to qualitatively converge the free energy of the permeation of long, flexible peptides.
- 13 June 2025
- Published by Springer Nature in Pharmaceutical Research
- Vol. 42 (6) , 1021-1033
Controlling Gastric Delivery of a GIP/GLP1 Peptide in Monkeys by Mucoadhesive SNAC Tablets
Objective Gastric delivery has been utilized for oral delivery of peptides. However, target site of the delivery is uncontrollable due to the housekeeping wave. In addition, dilution and spreading of peptides and permeation enhancers in the stomach may limit the oral peptide bioavailability. In this study, we developed mucoadhesive tablets containing SNAC and a GIP/GLP1 dual agonist peptide (LY) to localize the peptide delivery and minimize the dilution effect in the stomach. Methods The mucoadhesive tablets were prepared as bilayer or trilayer tablets with sodium alginate on one or both sides of the formulation layer (LY/SNAC). Mucoadhesion tests were conducted using a rotating cylinder mounted with isolated rat and minipig gastric tissues, and in vivo in monkeys. Oral bioavailability of the peptide was determined in monkeys via oral administration of the mucoadhesive tablets. Results The mucoadhesive tablets dissolved > 80% within 15 min at pH 6.8. The trilayer SNAC tablets adhered to the isolated gastric tissues. Following oral administration to monkeys, 10/10 mucoadhesive tablets were retained in the monkey stomach 10–20 min post-dose compared to 1/3 SNAC control tablets. Oral bioavailability of LY peptide was of similar magnitude as that achieved with the SNAC control tablet. In vivo dissolution of the mucoadhesive tablets was slower than the control tablets leading to lower SNAC concentration at the tablet site in the monkey stomach. Conclusion These data suggest that the mucoadhesive tablets improved gastric retention but did not increase oral bioavailability of the LY peptide following gastric delivery in monkeys.
- 13 June 2025
- Published by Springer Nature in Pharmaceutical Research
- Vol. 42 (6) , 1021-1033
Controlling Gastric Delivery of a GIP/GLP1 Peptide in Monkeys by Mucoadhesive SNAC Tablets
Objective Gastric delivery has been utilized for oral delivery of peptides. However, target site of the delivery is uncontrollable due to the housekeeping wave. In addition, dilution and spreading of peptides and permeation enhancers in the stomach may limit the oral peptide bioavailability. In this study, we developed mucoadhesive tablets containing SNAC and a GIP/GLP1 dual agonist peptide (LY) to localize the peptide delivery and minimize the dilution effect in the stomach. Methods The mucoadhesive tablets were prepared as bilayer or trilayer tablets with sodium alginate on one or both sides of the formulation layer (LY/SNAC). Mucoadhesion tests were conducted using a rotating cylinder mounted with isolated rat and minipig gastric tissues, and in vivo in monkeys. Oral bioavailability of the peptide was determined in monkeys via oral administration of the mucoadhesive tablets. Results The mucoadhesive tablets dissolved > 80% within 15 min at pH 6.8. The trilayer SNAC tablets adhered to the isolated gastric tissues. Following oral administration to monkeys, 10/10 mucoadhesive tablets were retained in the monkey stomach 10–20 min post-dose compared to 1/3 SNAC control tablets. Oral bioavailability of LY peptide was of similar magnitude as that achieved with the SNAC control tablet. In vivo dissolution of the mucoadhesive tablets was slower than the control tablets leading to lower SNAC concentration at the tablet site in the monkey stomach. Conclusion These data suggest that the mucoadhesive tablets improved gastric retention but did not increase oral bioavailability of the LY peptide following gastric delivery in monkeys.
- 1 November 2024
- Published by Springer Nature in Pharmaceutical Research
- Vol. 41 (11) , 2259-2270
Development of 3D-Printed Two-Compartment Capsular Devices for Pulsatile Release of Peptide and Permeation Enhancer
Objective The oral absorption of a peptide is driven by a high local concentration of a permeation enhancer (PE) in the gastrointestinal tract. We hypothesized that a controlled release of both PE and peptide from a solid formulation, capable of maintaining an effective co-localized concentration of PE and peptide could enhance oral peptide absorption. In this study, we aimed to develop a 3D-printed two-compartment capsular device with controlled pulsatile release of peptide and sodium caprate (C10). Methods 3D-printed two-compartment capsular device was fabricated using a fused deposition modeling method. This device was then filled with LY peptide and C10. The release profile was modulated by changing the thickness and polymer type of the capsular device. USP apparatus II dissolution test was used to evaluate the impacts of device thickness and polymer selection on release profile in vitro. An optimal device was then enteric coated with HPMCAS. Results A strong linear relationship between the thickness of capsular devices and the delay in the release onset time was observed. An increase in the device thickness or the use of PLA decreased the release rate. The capsular device with compartment 1, compartment 2 and fence thickness of 0.4; 0.95 and 0.5 mm, respectively, and the use of PVA achieved desired pulsatile release profiles of both peptide and C10. Furthermore, enteric-coated capsular devices with HPMCAS had similar pulsatile release profiles compared to non-enteric coated devices. Conclusion These findings suggest potential application of 3D-printing techniques in the formulation development for complex modified drug release products. Graphical Abstract The schematic diagram illustrates the design of a 3D-printed capsular devices to achieve pulsatile release profile.
- 1 November 2024
- Published by Springer Nature in Pharmaceutical Research
- Vol. 41 (11) , 2259-2270
Development of 3D-Printed Two-Compartment Capsular Devices for Pulsatile Release of Peptide and Permeation Enhancer
Objective The oral absorption of a peptide is driven by a high local concentration of a permeation enhancer (PE) in the gastrointestinal tract. We hypothesized that a controlled release of both PE and peptide from a solid formulation, capable of maintaining an effective co-localized concentration of PE and peptide could enhance oral peptide absorption. In this study, we aimed to develop a 3D-printed two-compartment capsular device with controlled pulsatile release of peptide and sodium caprate (C10). Methods 3D-printed two-compartment capsular device was fabricated using a fused deposition modeling method. This device was then filled with LY peptide and C10. The release profile was modulated by changing the thickness and polymer type of the capsular device. USP apparatus II dissolution test was used to evaluate the impacts of device thickness and polymer selection on release profile in vitro. An optimal device was then enteric coated with HPMCAS. Results A strong linear relationship between the thickness of capsular devices and the delay in the release onset time was observed. An increase in the device thickness or the use of PLA decreased the release rate. The capsular device with compartment 1, compartment 2 and fence thickness of 0.4; 0.95 and 0.5 mm, respectively, and the use of PVA achieved desired pulsatile release profiles of both peptide and C10. Furthermore, enteric-coated capsular devices with HPMCAS had similar pulsatile release profiles compared to non-enteric coated devices. Conclusion These findings suggest potential application of 3D-printing techniques in the formulation development for complex modified drug release products. Graphical Abstract The schematic diagram illustrates the design of a 3D-printed capsular devices to achieve pulsatile release profile.
- 7 December 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 650, 123680
Development and evaluation of C10 and SNAC erodible tablets for gastric delivery of a GIP/GLP1 peptide in monkeys
- 7 December 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 650, 123680
Development and evaluation of C10 and SNAC erodible tablets for gastric delivery of a GIP/GLP1 peptide in monkeys
- 2 January 2023
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 20 (2) , 929-941
In Vivo Mechanism of Action of Sodium Caprate for Improving the Intestinal Absorption of a GLP1/GIP Coagonist Peptide
Sodium caprate (C10) has been widely evaluated as an intestinal permeation enhancer for the oral delivery of macromolecules. However, the effect of C10 on the intestinal absorption of peptides with different physicochemical properties and its permeation-enhancing effect in vivo remains to be understood. Here, we evaluated the effects of C10 on intestinal absorption in rats with a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GIP-GLP1) dual agonist peptide (LY) and semaglutide with different enzymatic stabilities and self-association behaviors as well as the oral exposure of the LY peptide in minipigs. Furthermore, we investigated the mechanism of action (MoA) of C10 for improving the intestinal absorption of the LY peptide in vivo via live imaging of the rat intestinal epithelium and tissue distribution of the LY peptide in minipigs. The LY peptide showed higher proteolytic stability in pancreatin and was a monomer in solution compared to that in semaglutide. C10 increased in vitro permeability in the minipig intestinal organoid monolayer to a greater extent for the LY peptide than for semaglutide. In the rat jejunal closed-loop model, C10 increased the absorption of LY peptide better than that of semaglutide, which might be attributed to higher in vitro proteolytic stability and permeability of the LY peptide. Using confocal live imaging, we observed that C10 enabled the rapid oral absorption of a model macromolecule (FD4) in the rat intestine. In the duodenum tissues of minipigs, C10 was found to qualitatively reduce the tight junction protein level and allow peptide uptake to the intestinal cells. C10 decreased the transition temperature of the artificial lipid membrane, indicating an increase in membrane fluidity, which is consistent with the above in vivo imaging results. These data indicated that the LY's favorable physicochemical properties combined with the effects of C10 on the intestinal mucosa resulted in an ∼2% relative bioavailability in minipigs.
- 2 January 2023
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 20 (2) , 929-941
In Vivo Mechanism of Action of Sodium Caprate for Improving the Intestinal Absorption of a GLP1/GIP Coagonist Peptide
Sodium caprate (C10) has been widely evaluated as an intestinal permeation enhancer for the oral delivery of macromolecules. However, the effect of C10 on the intestinal absorption of peptides with different physicochemical properties and its permeation-enhancing effect in vivo remains to be understood. Here, we evaluated the effects of C10 on intestinal absorption in rats with a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GIP-GLP1) dual agonist peptide (LY) and semaglutide with different enzymatic stabilities and self-association behaviors as well as the oral exposure of the LY peptide in minipigs. Furthermore, we investigated the mechanism of action (MoA) of C10 for improving the intestinal absorption of the LY peptide in vivo via live imaging of the rat intestinal epithelium and tissue distribution of the LY peptide in minipigs. The LY peptide showed higher proteolytic stability in pancreatin and was a monomer in solution compared to that in semaglutide. C10 increased in vitro permeability in the minipig intestinal organoid monolayer to a greater extent for the LY peptide than for semaglutide. In the rat jejunal closed-loop model, C10 increased the absorption of LY peptide better than that of semaglutide, which might be attributed to higher in vitro proteolytic stability and permeability of the LY peptide. Using confocal live imaging, we observed that C10 enabled the rapid oral absorption of a model macromolecule (FD4) in the rat intestine. In the duodenum tissues of minipigs, C10 was found to qualitatively reduce the tight junction protein level and allow peptide uptake to the intestinal cells. C10 decreased the transition temperature of the artificial lipid membrane, indicating an increase in membrane fluidity, which is consistent with the above in vivo imaging results. These data indicated that the LY's favorable physicochemical properties combined with the effects of C10 on the intestinal mucosa resulted in an ∼2% relative bioavailability in minipigs.
- 1 September 2022
- Published by Springer Nature in Pharmaceutical Research
- Vol. 39 (10) , 2555-2567
Identification of a Multi-Component Formulation for Intestinal Delivery of a GLP-1/Glucagon Co-agonist Peptide
Purpose Oral delivery of therapeutic peptides has been challenging due to multiple physiological factors and physicochemical properties of peptides. We report a systematic approach to identify formulation compositions combining a permeation enhancer and a peptidase inhibitor that minimize proteolytic degradation and increase absorption of a peptide across the small intestine. Methods An acylated glucagon-like peptide-1/glucagon co-agonist peptide (4.5 kDa) was selected as a model peptide. Proteolytic stability of the peptide was investigated in rat and pig SIF. Effective PEs and multiple component formulations were identified in rats. Relative bioavailability of the peptide was determined in minipigs via intraduodenal administration (ID) of enteric capsules. Results The peptide degraded rapidly in the rat and pig SIF. Citric acid, SBTI, and SBTCI inhibited the enzymatic degradation. The peptide self-associated into trimers in solution, however, addition of PEs monomerized the peptide. C10 was the most effective PE among tested PEs (DPC, LC, rhamnolipid, C12-maltosides, and SNAC) to improve intestinal absorption of the peptide in the rat IJ-closed loop model. A combination of C10 and SBTI or SBTCI increased the peptide exposure 5–tenfold compared to the exposure with the PE alone in the rat IJ-cannulated model, and achieved 1.06 ± 0.76% bioavailability in minipigs relative to subcutaneous via ID administration using enteric capsules. Conclusion We identified SBTI and C10 as an effective peptidase inhibitor and PE for intestinal absorption of the peptide. The combination of SBTI and C10 addressed the peptide physiochemical properties and provides a formulation strategy to achieve intestinal delivery of this peptide.
- 1 September 2022
- Published by Springer Nature in Pharmaceutical Research
- Vol. 39 (10) , 2555-2567
Identification of a Multi-Component Formulation for Intestinal Delivery of a GLP-1/Glucagon Co-agonist Peptide
Purpose Oral delivery of therapeutic peptides has been challenging due to multiple physiological factors and physicochemical properties of peptides. We report a systematic approach to identify formulation compositions combining a permeation enhancer and a peptidase inhibitor that minimize proteolytic degradation and increase absorption of a peptide across the small intestine. Methods An acylated glucagon-like peptide-1/glucagon co-agonist peptide (4.5 kDa) was selected as a model peptide. Proteolytic stability of the peptide was investigated in rat and pig SIF. Effective PEs and multiple component formulations were identified in rats. Relative bioavailability of the peptide was determined in minipigs via intraduodenal administration (ID) of enteric capsules. Results The peptide degraded rapidly in the rat and pig SIF. Citric acid, SBTI, and SBTCI inhibited the enzymatic degradation. The peptide self-associated into trimers in solution, however, addition of PEs monomerized the peptide. C10 was the most effective PE among tested PEs (DPC, LC, rhamnolipid, C12-maltosides, and SNAC) to improve intestinal absorption of the peptide in the rat IJ-closed loop model. A combination of C10 and SBTI or SBTCI increased the peptide exposure 5–tenfold compared to the exposure with the PE alone in the rat IJ-cannulated model, and achieved 1.06 ± 0.76% bioavailability in minipigs relative to subcutaneous via ID administration using enteric capsules. Conclusion We identified SBTI and C10 as an effective peptidase inhibitor and PE for intestinal absorption of the peptide. The combination of SBTI and C10 addressed the peptide physiochemical properties and provides a formulation strategy to achieve intestinal delivery of this peptide.